OakChart

Delcath Systems Inc

DCTHHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 3:30 PM ET

22.00+1.90 (9.45%)
2026-11-11 21:30 CET
Market cap
697.45 USD m
Revenue, TTM
109.96 USD m
Net income, TTM
6.65 USD m
Free cash flow, TTM
20.11 USD m
EPS diluted, TTM
0.15
P/E
142.03
Compare

Price

DCTH against its 20, 50 and 200-day averages
2050200beat
10.0015.0020.001.7M3.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DCTHclose 22.0020-day 15.5050-day 15.71200-day 12.6022.00

1.4% under the 52-week high of 22.32 on 11 Nov 2026. 52-week low 8.12 on 20 Nov 2025. Last 15 sessions, 60.4% high to low

Volume 3.10× normal · the line is the 50-bar volume average

Profile

DCTH
52-week range, 100% of the way up
8.1221.84

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

IndexRUT
Employees156
IPOOct 23, 2001
Beta0.54
ATR, 14d1.11
Rel volume3.10
Short float5.53%
Insider own7.49%
Inst own60.50%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap765.34M
Enterprise Value663.44M
Income6.65M
Sales109.96M
Book/sh3.84
Cash/sh3.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees156
IPOOct 23, 2001

Ratios

P/E142.03
Forward P/E163.87
PEG2.64
P/S6.96
P/B5.73
P/C7.34
P/FCF38.06
EV/EBITDA105.47
EV/Sales6.03
Quick Ratio10.06
Current Ratio10.87
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)0.15
EPS next Y0.13
EPS next Q-0.09
EPS this Y-32.07%
EPS next Y182.33%
EPS next 5Y62.07%
EPS past 3/5Y- -
Sales past 3/5Y215.30% 120.21%
EPS Y/Y TTM709.17%
Sales Y/Y TTM38.13%
EPS Q/Q718.84%
Sales Q/Q70.70%
EarningsNov 09 BMO
EPS/Sales Surpr.285.39% 35.04%

Ownership

Insider Own7.49%
Insider Trans0.00%
Inst Own60.50%
Inst Trans2.25%
ROA4.87%
ROE5.36%
ROIC4.90%
Gross Margin87.59%
Oper. Margin5.17%
Profit Margin6.05%
SMA2041.94%
SMA5040.02%
SMA20074.59%
Trades-

Technical

Shs Outstand34.77M
Shs Float32.10M
Short Float5.53%
Short Ratio3.76
Short Interest1.78M
52W High21.84 0.73%
52W Low8.12 170.94%
Volatility8.48% 4.77%
ATR (14)1.11
RSI (14)82.03
Beta0.54
Rel Volume3.10
Avg Volume472.20K
Volume1,355,546

Performance

Perf Week48.45%
Perf Month43.60%
Perf Quarter26.73%
Perf Half Y89.49%
Perf YTD117.82%
Perf Year155.22%
Perf 3Y645.76%
Perf 5Y103.42%
Perf 10Y-100.00%
Recom1.00
Target Price27.33
Prev Close20.10
Price22.00
Change %9.45%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Jun 28, 2024InitiatedCCraig HallumBuy$18-18.2%
May 14, 2024InitiatedSStephensOverweight$25+13.6%
Jul 26, 2022ResumedCCanaccord GenuityBuy$17-22.7%
Dec 10, 2021InitiatedHH.C. WainwrightBuy$25+13.6%
Mar 09, 2021InitiatedCCanaccord GenuityBuy$24+9.1%
Jan 05, 2021InitiatedBBTIG ResearchBuy$23+4.5%
Jun 01, 2020InitiatedLLaidlawBuy$19-13.6%

Peers

Mkt cap
TickerCompanyMkt cap
IMCRImmunocore Holdings plc ADR1.63B
IDYAIdeaya Biosciences Inc3.15B
AURAAura Biosciences Inc788.36M
BSXBoston Scientific Corp65.49B
REPLReplimune Group Inc2.10B
CSTLCastle Biosciences Inc1.05B
ANGOAngiodynamic Inc517.24M
IOVAIovance Biotherapeutics Inc3.75B
NVCRNovoCure Ltd1.40B
PLSEPulse Biosciences Inc4.14B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Pennell SandraChief Financial OfficerMar 06 '26Buy9.045,53350,01877,018Mar 06 04:22 PM
Sylvester John RichardDirectorNov 21 '25Buy8.894,38638,99214,936Nov 25 04:15 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SURISimplify Propel Opportunities ETFAUM: 74.30M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
IWCiShares Micro-Cap ETFAUM: 1.22B
XHEState Street SPDR S&P Health Care Equipment ETFAUM: 160.14M

News

latest 14 of 200
  • Delcath Systems Reports 70% Revenue Growth in Q3 2026 and Raises Full-Year Guidance to $115 Million-$117 Million (InvestorsHub) +35.77%
  • Delcath Crushes Q3 Estimates And Raises Guidance Again, But An Implied Q4 Step-Down And Slipping Center Activations Complicate The Story (Earnings Whispers)
  • Delcath Systems Reports Third Quarter 2026 Results and Business Highlights (Business Wire)
  • Delcath Faces A Seasonality Test As Street Braces For Sequential Revenue Dip And Loss (Earnings Whispers)
  • Delcath Systems to Participate in Upcoming Investor Conferences (Business Wire)
  • Delcath Systems to Host Third Quarter 2026 Earnings Call (Business Wire)
  • Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma (Business Wire)
  • Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Delcath Systems to Participate in Upcoming Investor Conferences (Business Wire)
  • These Two Stocks Hit Fresh 52-Week Highs Today DCTH Clocks Best Day In Nearly 15 Months (Stocktwits) +22.49%
  • Delcath Systems Reports Second Quarter 2026 Results and Business Highlights (Business Wire)
  • Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
  • Delcath Systems to Host Second Quarter 2026 Earnings Call (Business Wire)
  • Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-090.170-0.0920.17035.1025.995
2026Q22026-08-060.070-0.0890.06729.1326.255
2026Q12026-05-07-0.030-0.097-0.03025.0023.517
2025Q42026-02-26-0.050-0.063-0.05220.7320.587
2025Q32025-11-040.020-0.0040.02120.5620.507
2025Q22025-08-060.0700.0270.06724.1622.947
2025Q12025-05-080.0300.0210.02719.8016.737
2024Q42025-03-06-0.110-0.001-0.10615.1013.627
2024Q32024-11-080.060-0.2000.05811.2010.466
2024Q22024-08-05-0.480-0.362-0.4847.775.166
2024Q12024-05-14-0.450-0.454-0.4463.142.225
2023Q42024-03-26-0.480-0.539-0.4820.540.554
2023Q32023-11-13-1.140-0.520-1.1390.430.685
2023Q22023-08-09-0.580-0.506-0.5780.500.845
2023Q12023-05-22-0.770-0.616-0.7740.600.725
2022Q42023-03-27-0.860-0.764-0.8580.640.845

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-694.91--342.821.58-
2020FY-8.350-7.547-8.3551.651.57
2021FY-3.590-3.882-3.5893.561.94
2022FY-4.120-3.773-4.1182.722.91
2023FY-2.940-3.014-2.9382.072.07
2024FY-0.930-0.774-0.92537.2135.72
2025FY0.0700.0500.07085.2385.08
2026FY-0.048--113.07
2027FY-0.134--138.2
2028FY-0.298--161.42
2029FY-0.558--188.03
2030FY-0.940--221.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0963026.9926.3027.80
2026Q4S2026-11-0460026.3024.9026.80
2026Q4S2026-11-0260026.3024.9026.80
2026Q4S2026-10-2060026.3124.9026.83
2026Q4S2026-09-1860226.3124.9026.83
2026Q4S2026-08-1060326.3124.9026.83
2026Q4S2026-08-0660326.3024.9026.80
2026Q4S2026-08-0450026.8126.3627.58
2026Q4S2026-07-2150026.8126.3627.58
2026Q4S2026-06-0950526.8126.3627.58
2026Q4S2026-06-0660626.7926.3627.58
2026Q4S2026-05-0770627.4526.3631.40
2026Q4S2026-05-0470529.6027.7133.70
2026Q4S2026-04-1370529.5927.7033.70

Estimate history

EPS, annual-2272727.273-503.847-342.819-8.355-3.589-4.118-2.938-0.9250.0680.1549
Period201720182019202020212022202320242025TTM
EPS, quarterly0.058-0.1060.0270.0670.021-0.052-0.030.0670.17
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.7153.4071.581.6463.5552.7192.06537.20585.231109.96
Period201720182019202020212022202320242025TTM
Sales, quarterly11.215.119.78424.15620.56320.72824.99429.13335.102
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual00.0150.0675.9967.9077.90722.76233.06134.69234.771
Period201720182019202020212022202320242025MRQ
Shares, quarterly28.0233.06133.43734.95635.30934.69234.46534.63634.771
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue109.9685.2337.202.062.723.561.651.583.41
Cost of Goods Sold Incl. D&A13.6511.806.190.761.260.670.642.511.01
Gross Profit96.3173.4331.021.301.462.881.01-0.932.40
Selling, General and Administrative Excl. Other90.6272.7743.4339.4835.3127.4122.3118.1829.47
Research and Development40.5929.2513.8717.5018.5813.7811.209.4919.65
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income5.690.66-12.41-38.18-33.85-24.53-21.30-19.11-27.07
Interest Expense---1.442.691.190.174.757.96
Unusual Expense0.000.0014.078.000.000.002.83-16.69-18.58
Net Income Before Taxes8.883.51-26.39-47.68-36.51-25.65-24.16-8.88-19.22
Income Taxes2.230.810.000.000.000.000.000.000.00
Consolidated Net Income6.652.70-26.39-47.68-36.51-25.65-24.16-8.88-19.22
Net Income From Continuing Operations6.652.70-26.39-47.68-36.51-25.65-24.16-8.88-19.22
Net Income6.652.70-26.39-47.68-36.51-25.65-24.21-8.88-19.22
EPS (Recurring)0.160.07-0.58-2.59-4.12-3.59-7.67-793.98-844.81
EPS (Basic, Before Extraordinaries)0.190.08-0.93-2.94-4.12-3.59-8.35-342.82-503.85
EPS (Diluted)0.150.07-0.93-2.94-4.12-3.59-8.35-342.82-503.85
EBITDA6.291.01-12.18-38.05-33.28-24.06-21.11-17.32-26.63
Non-Operating Income (Expense)3.192.850.10-0.060.030.070.15-1.72-2.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.8619.149.778.157.947.833.500.270.06
Price To Earnings Ratio129.76129.76------0.12
Price To Sales Ratio5.964.739.2332.7011.7415.5831.550.352.20
Gross Margin87.5986.1683.3763.0553.6281.1361.12-58.7370.38
Operating Margin5.170.77-33.36-1,849.01-1,245.05-690.04-1,294.23-1,209.37-794.57
Net Margin6.053.17-70.92-2,308.86-1,342.70-721.49-1,470.90-561.96-564.19
Shares Outstanding34.7734.6933.0622.767.917.916.000.070.01
Market Capitalization697.45697.45384.9691.7130.9557.01106.600.842.87

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue35.1029.1324.9920.7320.5624.1619.7815.10
Cost of Goods Sold Incl. D&A3.922.983.743.012.623.322.852.13
Gross Profit31.1826.1521.2617.7217.9420.8416.9412.97
Selling, General and Administrative Excl. Other24.0723.7522.8919.9018.3318.2516.309.94
Research and Development11.0110.389.829.377.996.885.012.91
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income7.122.40-1.64-2.18-0.392.590.643.04
Interest Expense0.000.00------
Unusual Expense0.000.000.000.000.000.000.006.68
Net Income Before Taxes7.973.16-0.91-1.330.383.211.26-3.40
Income Taxes1.010.490.160.56-0.460.510.200.00
Consolidated Net Income6.952.67-1.07-1.900.832.701.07-3.40
Net Income From Continuing Operations6.952.67-1.07-1.900.832.701.07-3.40
Net Income6.952.67-1.07-1.900.832.701.07-3.40
EPS (Recurring)0.170.07-0.03-0.050.020.070.030.04
EPS (Basic, Before Extraordinaries)0.190.07-0.03-0.050.020.080.03-0.11
EPS (Diluted)0.170.07-0.03-0.050.020.070.03-0.11
EBITDA7.322.55-1.51-2.08-0.302.670.713.11
Non-Operating Income (Expense)0.850.760.730.850.760.610.620.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.344.043.913.564.515.755.481.61
Price To Earnings Ratio129.762,098.33148.011,174.42236.26---
Price To Sales Ratio5.965.253.704.325.417.809.3410.36
Gross Margin88.8489.7585.0585.4887.2486.2685.6285.92
Operating Margin20.278.22-6.55-10.54-1.8910.723.2520.13
Net Margin19.819.16-4.28-9.154.0411.165.40-22.50
Shares Outstanding34.7734.6434.4734.6935.3134.9633.4433.06
Market Capitalization697.45434.63322.44356.67376.05473.64425.22384.96

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments91.0453.2332.5011.8226.9528.7610.183.585.32
Short Term Receivables12.2411.020.390.370.040.060.051.160.32
Inventories10.256.933.322.001.410.850.650.861.25
Other Current Assets6.002.580.941.972.742.671.730.320.63
Total Current Assets119.5373.7637.1616.1631.1532.3412.625.927.52
Net Property, Plant & Equipment4.102.831.461.711.972.301.590.931.30
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets38.35--------
Other Assets0.000.000.000.000.000.000.000.000.07
Total Assets161.9976.5938.6117.8633.1234.6314.216.848.89
Short Term Debt Incl. Current Port. of LT Debt0.100.1010.198.031.042.500.662.040.00
Accounts Payable2.660.961.012.020.641.774.537.713.85
Other Current Liabilities8.195.085.254.684.285.7710.318.003.97
Total Current Liabilities10.956.1416.4514.735.9510.0415.5117.757.81
Long Term Debt0.830.930.848.9915.220.452.200.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.200.40
Deferred Tax Liabilities38.35--------
Other Liabilities0.630.775.550.000.002.072.863.83-0.01
Total Liabilities50.777.8422.8423.7221.1712.5620.5721.788.21
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity111.2268.7515.78-5.8611.9522.08-6.36-14.940.68
Total Shareholders Equity111.2268.7515.78-5.8611.9522.08-6.36-14.940.68
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity111.2268.7515.78-5.8611.9522.08-6.36-14.940.68
Total Liabilities & Stockholders Equity161.9976.5938.6117.8633.1234.6314.216.848.89
Book Value Per Share3.212.080.69-0.741.513.68-94.75-1,022.222,078.50
Tangible Book Value Per Share3.212.080.69-0.741.513.68-94.75-1,022.222,078.50
Full-Time Employees1569676525536334346
Price to Book Ratio5.2339.363.31-5.905.134.87-0.22-0.19-0.07
Return on Assets2.26-45.81-168.85-143.21-75.71-98.90-84.34-244.38-204.49
Return on Equity3.00-62.44-961.44-1,198.36-150.74-307.31---
Return on Invested Capital2.41-37.87-286.92-1,167.51-94.40-107.23---6,654.42
Quick Ratio9.9810.882.060.964.993.140.770.290.80
Current Ratio10.9212.012.261.105.233.220.810.330.96

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income6.652.70-26.39-47.68-36.51-25.65-24.16-8.88-19.22
Depreciation0.610.350.230.130.570.470.191.790.44
Other Funds (Non Cash)17.0222.5423.0017.208.878.346.90-9.50-7.73
Funds from Operations24.2925.59-3.16-30.34-27.06-16.84-17.06-16.59-26.50
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.29-3.07-15.52-0.912.11-5.76-5.81-7.1011.77
Cash from Operating Activities22.9922.52-18.68-31.25-24.95-22.60-22.87-23.69-14.73
Capital Expenditures-2.88-1.55-0.56-0.06-0.21-0.14-0.78-0.02-0.08
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-0.01-25.04-0.42-19.650.000.000.000.000.00
Purchase of Investments-95.98-93.22-52.45-19.650.000.000.000.000.00
Sale Or Maturity of Investments95.9768.1752.030.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.90-26.59-0.98-19.71-0.21-0.14-0.78-0.02-0.08
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-6.2715.0550.0258.0910.866.3842.3826.6212.44
Repurchase of Common Pref Stock-9.01-6.000.000.000.000.00-0.110.000.00
Sale of Common Pref Stock2.7421.0550.0258.0910.866.3842.4926.6212.44
Proceedsfrom Stock Options0.000.006.7722.9610.863.9240.6326.6212.44
Issuance or Reduction of Debt, Net0.000.00-10.61-6.31-0.7114.44-0.033.680.79
Change in Long Term Debt0.000.000.000.000.000.00-0.033.680.00
Issuance of Long Term Debt0.000.000.000.000.000.000.003.720.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.03-0.040.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-6.2715.0539.4151.7810.1420.8242.3530.3013.24
Exchange Rate Effect-0.100.07-0.030.06-0.120.12-0.130.01-0.17
Net Change in Cash13.7211.0419.720.87-15.13-1.8018.576.61-1.75
Free Cash Flow20.1120.97-19.24-31.31-25.16-22.75-23.65-23.71-14.81
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.000.00
Price to Free Cash Flow32.5719.23-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments104.3195.9089.3091.0488.9181.00
Short Term Receivables20.7116.2714.7412.2414.4616.28
Inventories10.5011.719.8110.2510.7410.52
Other Current Assets6.036.656.426.006.505.67
Total Current Assets141.56130.54120.27119.53120.61113.48
Net Property, Plant & Equipment7.546.484.574.103.683.39
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets---38.35--
Other Assets0.000.000.000.000.000.00
Total Assets149.09137.02124.84161.99124.30116.88
Short Term Debt Incl. Current Port. of LT Debt0.200.200.090.100.110.12
Accounts Payable3.484.013.462.662.134.72
Other Current Liabilities9.359.077.148.195.775.60
Total Current Liabilities13.0213.2810.7010.958.0110.44
Long Term Debt2.212.270.810.830.850.88
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---38.35--
Other Liabilities0.320.330.610.630.580.58
Total Liabilities15.5515.8712.1350.779.4511.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity133.54121.14112.71111.22114.85104.99
Total Shareholders Equity133.54121.14112.71111.22114.85104.99
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity133.54121.14112.71111.22114.85104.99
Total Liabilities & Stockholders Equity149.09137.02124.84161.99124.30116.88
Book Value Per Share3.843.503.273.213.253.00
Tangible Book Value Per Share3.843.503.273.213.253.00
Full-Time Employees---156--
Price to Book Ratio5.233.852.893.113.585.67
Return on Assets4.870.420.532.261.542.96
Return on Equity5.360.470.583.001.944.09
Return on Invested Capital5.122.16-0.94-1.690.722.55
Quick Ratio10.068.9510.339.9813.719.87
Current Ratio10.879.8311.2410.9215.0610.88

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income6.952.67-1.07-1.900.832.70
Depreciation0.200.170.130.110.090.08
Other Funds (Non Cash)3.784.684.514.055.176.75
Funds from Operations10.937.523.572.276.109.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.76-1.81-2.715.98-1.32-2.23
Cash from Operating Activities8.185.710.868.254.777.29
Capital Expenditures-1.26-0.50-0.57-0.55-0.46-0.40
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.00-0.00-0.00-0.01-0.01-0.02
Purchase of Investments-16.09-32.29-15.81-31.78-10.28-21.09
Sale Or Maturity of Investments16.0932.2915.8131.7710.2721.07
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.26-0.50-0.57-0.56-0.47-0.41
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.100.96-2.38-5.943.1014.64
Repurchase of Common Pref Stock0.00-0.01-3.00-6.000.000.00
Sale of Common Pref Stock1.100.970.620.063.1014.64
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.100.96-2.38-5.943.1014.64
Exchange Rate Effect0.010.04-0.05-0.10-0.010.13
Net Change in Cash8.026.21-2.141.647.3921.64
Free Cash Flow6.925.210.297.704.316.89
Price to Free Cash Flow32.5728.5917.4217.5535.78141.60

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 37.21M 2025: 85.23M
Non-US2024: 4.90M 2025: 6.40M
United States2024: 32.30M 2025: 78.84M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.53%1.8M32.1M462.58K
2026-10-155.87%1.9M32.1M469.29K
2026-09-306.07%1.9M32.1M479.39K
2026-09-157.20%2.3M32.1M517.80K
2026-08-316.98%2.2M32.1M565.28K
2026-08-147.34%2.4M32.1M564.61K
2026-07-317.90%2.5M32.1M485.24K
2026-07-158.45%2.7M31.9M473.24K
2026-06-308.99%2.9M31.9M459.11K
2026-06-1510.33%3.3M31.9M413.65K
2026-05-299.75%3.1M31.9M385.33K
2026-05-1510.75%3.4M31.9M401.48K
2026-04-3011.12%3.5M31.9M404.22K
2026-04-1512.13%3.9M31.8M434.95K
2026-03-3111.75%4.0M33.7M473.35K
2026-03-1312.19%4.1M33.7M493.09K
2026-02-2711.85%4.0M33.7M510.86K
2026-02-1311.77%4.0M34.3M573.57K
2026-01-3012.47%4.2M33.8M653.86K
2026-01-1512.93%4.4M33.8M816.10K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5017.5021.500.000.0000.000.000.995-0.0180.000
call5.0015.0019.0011.0012.4233.000.000.992-0.0190.001
call7.5012.5015.4012.046.50063.000.000.989-0.0190.001
call10.0011.2012.5011.304.1511862.000.970-0.0420.002
call12.508.809.709.712.41427520.000.981-0.0180.002
call15.005.007.506.402.45049138.000.973-0.0170.002
call17.503.104.804.701.7701935.000.958-0.0160.003
call20.001.652.301.800.7392701790.708-0.0960.012
call22.500.350.600.550.58819421.000.521-0.1320.014
call25.000.000.150.050.71313.003.000.129-0.0290.007
call30.000.001.400.421.3299.000.000.079-0.0380.005
put2.500.000.050.006.2420.000.00-0.005-0.0160.001
put5.000.004.900.184.5857.000.00-0.008-0.0190.001
put7.500.004.903.603.34732.000.00-0.011-0.0180.001
put10.000.001.350.282.53030.000.00-0.014-0.0180.001
put12.500.001.350.611.8761400.00-0.019-0.0170.002
put15.000.000.300.061.90760.000.00-0.088-0.0570.005
put17.500.000.050.131.08453.000.00-0.083-0.0310.005
put20.000.001.050.851.3678.000.00-0.310-0.0880.012
put22.500.754.900.003.4110.000.00-0.479-0.1300.014
put25.002.505.500.002.6120.000.00-0.870-0.0260.007
put30.006.4010.000.003.0960.000.00-0.921-0.0340.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-27SCHEDULE 13GSEC
2026-10-19SCHEDULE 13D/ASEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-08-14S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-148-KCurrent report2026-08-12SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-28SCHEDULE 13GSEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-148-KCurrent report2026-05-13SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-27SCHEDULE 13G/ASEC
2026-04-02ARSAnnual report to security holders. 2025-12-31SEC
2026-04-02DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-13SEC
2026-03-20SCHEDULE 13GSEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-06SEC
2026-03-034Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-038-KCurrent report2026-03-03SEC
2026-02-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-268-KCurrent report2026-02-26SEC
2026-02-184Statement of changes in beneficial ownership of securities2026-02-17SEC
2026-02-184Statement of changes in beneficial ownership of securities2026-02-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0350.02K100
2026-020000
2026-010000
2025-120000
2025-11137.04K200

Institutional holders

Manager% owned
Rosalind Advisors, Inc.9.56%
BlackRock, Inc.7.84%
VANGUARD CAPITAL MANAGEMENT LLC3.54%
Propel Bio Management, LLC2.52%
GEODE CAPITAL MANAGEMENT, LLC2.37%
STATE STREET CORP1.97%
ALGERT GLOBAL LLC1.68%
MILLENNIUM MANAGEMENT LLC1.64%
Divisadero Street Capital Management, LP1.45%
MORGAN STANLEY1.18%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.58%
iShares Russell 2000 ETF2.19%
Fidelity Small Cap Index Fund0.91%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
Simplify Propel Opportunities ETF0.76%
BlackRock Advantage Small Cap Core Fund0.67%
iShares Russell 2000 Value ETF0.67%
NORTH SQUARE DYNAMIC SMALL CAP FUND0.65%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
College Retirement Equities Fund - Total Global Stock Account0.41%

OakChart. DCTH. Cached 15 minutes.